Collectively, our data suggested that the synergistic inhibition of MEK and PI3K pathways, rather than selective inhibition of each pathway, achieved sufficient cytotoxic effects in EGFR-TKI resistant NSCLC cell lines, H1975, H460, and A549. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.